Education in the Spotlight
This carefully selected group of stocks features companies that could benefit from McGraw Hill's upcoming $4.2 billion IPO. Our professional analysts have identified these educational publishers, digital platforms, and service providers as potential beneficiaries of renewed investor interest in the education sector.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
McGraw Hill's planned $4.2 billion IPO could be a game-changer for the education sector, drawing fresh capital and attention to the entire industry. This event may trigger a reevaluation of valuations across educational companies, from traditional publishers to innovative digital learning platforms.
What You Need to Know
This is an event-driven investment opportunity based on a potential sentiment shift in the education industry. The companies in this group represent different segments of the educational ecosystem, offering diverse exposure to traditional publishing, online learning, and educational technology.
Why These Stocks
These companies were handpicked to provide a comprehensive cross-section of the education market. They include established publishers, online learning platforms, and for-profit institutions that could all benefit from increased market attention following McGraw Hill's high-profile return to the public markets.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+93.73%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 93.73% over the next year.
Stocks Rated Buy by Analysts
9 of 10 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 8.9% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
IPO Ripple Effect
McGraw Hill's $4.2 billion valuation could trigger a reassessment of how much other education companies are worth. This potential valuation boost might happen quickly as the IPO draws attention to the entire sector.
Digital Learning Revolution
Many companies in this group are at the forefront of transforming education through technology. Their innovative platforms are changing how people learn globally, creating growth opportunities that savvy investors are noticing.
Renewed Analyst Coverage
High-profile IPOs typically attract fresh research coverage and institutional investment to an entire sector. This increased attention could benefit all education stocks as analysts take a closer look at this evolving industry.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.